Saturday 17 October 2026 Export APYX’s income statement to Excel — free account

Apyx Medical Corporation

Apyx Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.8 million, up 9.86% from fiscal 2024. In the quarter to June 2026, revenue grew 22.1%, EPS grew 22.2%, free cash flow fell 137.4% and total debt rose 2.74%, each against the same quarter a year earlier.

2.55 0.01 −0.39%

Follow APYX

Alert me

Market cap: $107.8M
P/E: 0.0×
Fwd P/E: −16.0×
Dividend yield: —
F-score: 4/9
Altman Z: 1.10
Beneish M: −2.63
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 16.97%

Capital & Financial Ratios $m

Market Cap 107.84

Revenue 58.42

Net Income (8.41)

Free Cash Flow (11.05)

Net Debt 7.71

Current Ratio 5.68

Debt/Equity 3.19

P/E ratio 0.00

Fwd P/E (16.00)

P/S ratio 1.91

P/B ratio 10.08

Past 5Y EPS Growth —

This Y EPS Growth 1.85%

Next Y EPS Growth 5.03%

Next Y revenue growth 12.43%

Next 5Y EPS Growth 28.19%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 26.29%

10-year low 10-year high

P/B against its own 10 years 84.69%

10-year low 10-year high

EV/Sales against its own 10 years 31.44%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	44	32	32	28
Receivables	14	15	17	14
Inventory	10	8	9	11
Other	—	—	—	—
	70	56	58	53

	2023	2024	2025	Q'26
Payables	3	3	3	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	13	11	12	9

Compound Annual Growth %

	10y	5y	3y
Sales	6.00%	13.78%	5.89%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(4.46%)	(25.32%)	(26.79%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	12	14	—	—	—
’25	9	11	13	19	53
’24	10	12	11	14	48
’23	12	14	12	15	52
’22	12	10	9	13	45
’21	9	11	12	17	49
’20	5	4	7	11	28

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(3)	—	—	—
’25	(1)	(1)	(4)	(3)	(8)
’24	(6)	(4)	(4)	(3)	(18)
’23	(2)	(5)	4	(2)	(5)
’22	(5)	(6)	(5)	(5)	(20)
’21	(2)	(5)	(4)	0	(10)
’20	(7)	(5)	(3)	(1)	(16)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(4)	—	—	—
’25	(1)	(1)	(4)	(3)	(9)
’24	(6)	(5)	(5)	(3)	(19)
’23	(2)	2	4	(2)	1
’22	(5)	(6)	(6)	(5)	(21)
’21	(2)	(5)	(4)	0	(11)
’20	(7)	(5)	(3)	(1)	(17)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.05)	(0.07)	—	—	—
’25	(0.10)	(0.09)	(0.05)	(0.03)	(0.27)
’24	(0.22)	(0.19)	(0.14)	(0.12)	(0.66)
’23	(0.10)	(0.03)	(0.13)	(0.28)	(0.54)
’22	(0.17)	(0.16)	(0.17)	(0.17)	(0.67)
’21	(0.14)	(0.12)	(0.12)	(0.06)	(0.44)
’20	(0.06)	(0.14)	(0.11)	(0.04)	(0.35)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	3.55	2.81	6.71	1.31	1.41	0.97	0.76	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	8.89	8.59	17.50	13.78	7.97	2.80	4.44
People
People	Employees	217	211	222	266	266	272	276	252	220	205
	Revenue/emp, $m	0.04	0.05	0.07	0.11	0.10	0.18	0.16	0.21	0.22	0.26
Income, $m
Income, $m	Revenue	9	10	17	28	28	49	45	52	48	53
	Gross margin, %	58.01	67.99	65.20	67.63	63.17	69.26	65.45	64.49	61.04	62.53
	EBT	(11)	(14)	(15)	(20)	(19)	(15)	(23)	(21)	(23)	(11)
	EBT margin, %	(130.24)	(135.22)	(88.47)	(70.25)	(70.04)	(30.55)	(51.47)	(40.65)	(48.45)	(20.50)
	Net income	(4)	(5)	63	(20)	(12)	(15)	(23)	(19)	(24)	(11)
	Depreciation	1	1	1	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	0.32	0.33	0.50	0.83	0.81	1.41	1.29	1.51	1.35	1.29
	Earnings	(0.14)	(0.16)	1.93	(0.58)	(0.35)	(0.44)	(0.67)	(0.54)	(0.66)	(0.27)
	Cash flow	(0.10)	(0.12)	(0.63)	(0.54)	(0.47)	(0.30)	(0.59)	(0.15)	(0.51)	(0.19)
	Capex	(0.01)	(0.02)	(0.01)	(0.04)	(0.02)	(0.02)	(0.03)	0.19	(0.02)	(0.03)
	Free cash flow	(0.11)	(0.14)	(0.64)	(0.58)	(0.49)	(0.33)	(0.62)	0.04	(0.53)	(0.22)
	Book value	0.96	0.70	2.63	2.09	1.87	1.57	1.09	0.78	0.40	0.36
	Shares, m	27	31	33	34	34	34	35	35	36	41
Valuation, ×
Valuation, ×	P/E	3.37	3.37	3.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	13.06	13.06	13.06	10.21	8.89	9.07	1.95	1.77	1.17	2.72
	P/B	2.50	2.50	2.50	4.04	3.86	8.15	2.30	3.43	3.92	9.70
	EV/Sales	8.38	8.38	8.38	8.16	7.40	8.44	1.73	1.74	1.40	2.95
	EV/FCF	(6.58)	(6.58)	(6.58)	(11.65)	(12.31)	(36.66)	(3.62)	61.22	(3.58)	(17.10)
Cash, $m
Cash, $m	Operating cash flow	(3)	(4)	(21)	(18)	(16)	(10)	(20)	(5)	(18)	(8)
	Capex	0	(1)	0	(1)	(1)	(1)	(1)	7	(1)	(1)
	Free cash flow	(3)	(4)	(21)	(20)	(17)	(11)	(21)	1	(19)	(9)
Balance, $m
Balance, $m	Working capital	21	17	81	64	57	48	31	58	46	47
	Total debt	3	3	0	0	0	0	0	33	34	35
	Net debt	(12)	(8)	(78)	(58)	(42)	(31)	(10)	(10)	2	3
	Shareholders’ equity	26	22	87	71	64	54	38	27	14	15
Returns, %
Returns, %	ROA	(11.87)	(15.32)	98.84	(21.81)	(14.98)	(21.24)	(38.48)	(28.57)	(32.57)	(17.03)
	ROIC	(51.51)	(62.17)	(98.67)	(101.36)	(56.73)	(38.99)	(53.21)	(65.34)	(71.30)	(22.44)
	ROE	(15.92)	(20.98)	114.86	(24.88)	(17.61)	(25.74)	(50.51)	(57.83)	(113.74)	(76.88)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
QTRX Quanterix Corporation	$145.2M	— (loss-making)	— (loss-making)	+34.44% (above 0%: growing)	n/m	+18.92% (above 0%: growing)	38.52%	(150.22%)	Compare
MXCT MaxCyte, Inc.	$134.2M	— (loss-making)	— (loss-making)	−14.53% (below 0%: shrinking)	n/m	+54.74% (above 0%: growing)	76.96%	(140.72%)	Compare
OWLT Owlet, Inc.	$129.8M	— (loss-making)	— (loss-making)	+29.94% (above 0%: growing)	n/m	+55.74% (above 0%: growing)	64.44%	5.14%	Compare
APYX Apyx Medical Corporation	$107.8M	— (loss-making)	— (loss-making)	+22.08% (above 0%: growing)	n/m	−137.38% (below 0%: shrinking)	63.89%	(13.01%)
LUCD Lucid Diagnostics Inc.	$105.7M	— (loss-making)	— (loss-making)	+26.74% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	1.97%	(868.45%)	Compare
ZOMDF Zomedica Corp.	$95.4M	— (loss-making)	— (loss-making)	+36.59% (above 0%: growing)	n/m	+40.48% (above 0%: growing)	63.51%	(42.92%)	Compare
HYPR Hyperfine, Inc.	$82.7M	— (loss-making)	— (loss-making)	+44.81% (above 0%: growing)	n/m	+13.43% (above 0%: growing)	50.72%	(216.93%)	Compare
SERA Sera Prognostics, Inc.	$80.1M	— (loss-making)	— (loss-making)	+76.47% (above 0%: growing)	n/m	−10.58% (below 0%: shrinking)	(66.67%)	(33,346.67%)	Compare
LUNG Pulmonx Corporation	$79.5M	— (loss-making)	— (loss-making)	−4.62% (below 0%: shrinking)	n/m	−31.79% (below 0%: shrinking)	77.97%	(39.80%)	Compare
Median of peers	$100.5M	—	—	+32.19%	—	+16.18%	57.12%	(145.47%)

All 149 Medical Devices stocks →

Apyx Medical Corporation (APYX) key facts

Strength: Apyx Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.8 million, up 9.86% from fiscal 2024.
Apyx Medical Corporation (APYX) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, APYX traded at $2.55, a market capitalization of $107.8 million.
Return on equity was −76.9% and debt-to-equity 3.19.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.10 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.